Granules India Limited has announced its earnings conference call for the third quarter of FY26, scheduled for January 23, 2026 at 6:00 PM IST. The pharmaceutical company will discuss its financial performance and provide business updates during the analyst and investor call.

Conference Call Details

The earnings call has been scheduled under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided multiple access options for participants, including domestic and international dial-in numbers.

Key Participants

The earnings call will feature senior leadership from Granules India, providing comprehensive insights into the company's quarterly performance. The management team includes key executives from various operational areas.

Access Information

Participants can join the conference call through multiple channels, with both domestic and international access numbers provided. The company has also arranged for pre-registration to streamline the process.

Company Profile

Granules India Limited operates in the pharmaceuticals sector and is classified as a mid-cap company with a market capitalization of ₹13,840.60 crores. The company is listed on both NSE (symbol: GRANULES) and BSE (code: 532482), with its registered office located in Hyderabad, Telangana.

The scheduled earnings call represents the company's commitment to maintaining transparency and regular communication with stakeholders regarding its financial performance and strategic developments.

Shares of Granules India Ltd. gave up early gains on Thursday, January 8, despite its US-based subsidiary receiving tentative approval from the US drug regulator with 180-day exclusivity for a drug that treats attention deficit hyperactivity disorder (ADHD).

FDA Approval Details

The company's wholly-owned subsidiary Granules Pharmaceuticals Inc. has received the US Food and Drug Administration's tentative approval for its abbreviated new drug application for generic Amphetamine Extended-Release Tablets. The approval covers multiple strengths including 5mg, 10mg, 15mg and 20mg formulations, serving as the generic equivalent of DYANAVEL XR.

Additional ADHD Portfolio Expansion

Granules announced on December 22 that it had received tentative approval for Amphetamine Extended-Release Orally Disintegrating Tablets in six different strengths: 3.1mg, 6.3mg, 9.4mg, 12.5mg, 15.7mg and 18.8mg. This drug serves as the generic equivalent of ADZENYS XR-ODT, also for ADHD treatment.

Strategic Market Position

"Having a product that is eligible for 180-day exclusivity, Granules strongly validates our long-term strategy of building a differentiated portfolio of complex generics," said Krishna Prasad Chigurupati, the chairman and managing director of Granules India.

The 180-day exclusivity period provides Granules with a significant competitive advantage, allowing the company to be among the first to market these generic ADHD treatments before other competitors can enter.

Stock Performance

Shares of Granules India are currently trading little changed on Thursday at ₹611.90. The stock has remained flat over the last 12 months, showing minimal movement despite the regulatory achievements in the ADHD treatment segment.